***PRRT2*-dependent dyskinesia: cerebellar, paroxysmal and persistent**

Cell Research (2018) 28:3–4. doi:10.1038/cr.2017.142; published online 17 November 2017

In an elegant publication in *Cell Research*, Tan and colleagues showed that ablation of *PRRT2* in cerebellar granule cells is sufficient to induce paroxysmal kinesigenic dyskinesia. *PRRT2* turns out to downregulate the presynaptic SNARE complex in granule cell axons, which in turn controls the activity patterns of Purkinje cells, the sole output of the cerebellar cortex.

It has recently been shown that patients with mutations in the proline-rich transmembrane protein 2 (*PRRT2*) can suffer from paroxysmal kinesigenic dyskinesia (PKD) [1], but the pathophysiological mechanisms underlying the relation between the genetic alterations and severe episodic attacks of dyskinesia and dystonia have remained unclear. To unravel these mechanisms, Tan and colleagues generated several mouse models harboring global neuronal or region-specific *PRRT2* truncations [2]. Mutant mice with global or cerebellum-specific truncation, but not forebrain-specific truncation, exhibited, similar to the clinical features of PKD in patients, severe episodes of aberrant motor behavior including dyskinesia and dystonic postures following generalized seizures and hyperthermia. These manifestations, which point towards a prime role for cerebellar dysfunction in this form of PKD, were corroborated by electron microscopic and electrophysiological analyses of the cerebellar granule cell, i.e., parallel fiber, to Purkinje cell input (Figure 1). *PRRT2* was found to be prominently present in the presynaptic segments of the parallel

fiber terminals and stimulation of these fibers in mutants with truncated *PRRT2* resulted in a transient biphasic elevation and suppression of simple spike firing of Purkinje cells, promoting abnormal firing patterns. Accordingly, truncation of *PRRT2* increased the mEPSC frequency and number of docked vesicles at the parallel fiber to Purkinje cell input (Figure 1), which is in line with an inhibitory control function in neurotransmission at the presynaptic level. Indeed, using a diverse series of binding assays, the authors uncovered that *PRRT2* inhibits several proteins of the presynaptic SNARE complex.

This paper provides the first direct evidence for a link between *PRRT2*-associated dyskinesia and specific cerebellar presynaptic deficits. *PRRT2* has been suggested before to play a role in the release machinery of presynaptic vesicles [3] and interact with the SNARE complex [4], but this interaction was never demonstrated to be involved in PKD, let alone to be critical for cerebellar function [5]. Interestingly, cerebellar deficits in Purkinje cell activity have recently also been shown to contribute to Rapid Onset Dystonian Parkinsonism (RODP), another paroxysmal movement disorder, which is caused by a mutation in a sodium-potassium ATPase pump [6]. By providing the next example of a paroxysmal movement disorder that primarily originates in the cerebellum, rather than in the basal ganglia-thalamic circuit, the current paper is further opening up the avenue of research that aims to elucidate how deficits in the activity

of Purkinje cells and/or that of their inputs can lead to movement disorders like PKD and RODP. So far, various *in vivo* datasets indicate that bursty and irregular Purkinje cell activity can result in abnormal movements, including not only dystonic [7, 8] but also ataxic [9] movements. The current *in vitro* data obtained from *PRRT2* mutants support this hypothesis in that the firing frequency of their Purkinje cell activity following optogenetic stimulation of their parallel fiber input was transiently and biphasically increased and decreased as compared to wild-type cells. Question remains, which factors determine the duration of these episodes (often tens of minutes rather than seconds)? Does it merely depend on the initial event that evoked the abnormal firing pattern of Purkinje cells, which could include for example a period with seizures, stress or hyperthermia [2], or does it also depend on internal amplification mechanisms, such as those that are mediated by the projections from the cerebellar nuclei neurons to the granule cells in the cerebellar cortex [10] (Figure 1)? Given the similarities in duration of the behavioral and cerebellar neuronal correlates of the paroxysmal attacks in RODP mice [7, 8] and that of the dysfunctional motor episodes in the murine models described in the paper by Tan and colleagues [2], it appears plausible that in both RODP and PKD prolonged interactive, yet erratic, firing patterns of Purkinje cells and their downstream targets in the nuclei underlie the pathological motor behavior.

Thus, future research on *PRRT2*-

Figure 1 Potential cerebellar circuit mechanism contributing to *PRRT2*-dependent dyskinesia. The Purkinje cells (PCs) in the cerebellar cortex (Cbx) inhibit neurons in the cerebellar nuclei (CN), which in turn excite the thalamus (Th) and its networks with the cerebral cortex (Cx) and basal ganglia (BG) (left panel). The axons of the neurons in the cerebellar nuclei (CNN), which can drive motor behavior via these networks, provide recurrent nucleo-cortical fibers (NCF) innervating the granule cell layer in the cerebellar cortex (middle panel). This innervation may contribute to long-term changes in activity of the granule cells (GCs), which in turn modulate the PCs via their parallel fibers (PFs). As shown in the recent paper by Tan and colleagues, the transmission between PFs and PCs can be prominently affected by truncation of *PRRT2*. Ablation of *PRRT2* results in reduced downregulation of the SNARE complex, an increase in docked vesicles and facilitated neurotransmission (right panel top). Upon stimulation, these changes in PF to PC transmission may lead to highly irregular cerebellar cortical and nuclear output (right panel bottom). Thus, once this activity in both the PCs and CNNs is aberrant, it may persist for long periods because of NCFs, generating a pathological reverberating loop prolonging the dyskinesia. Please note that the PC and CNN data in the right bottom panel were not recorded simultaneously and merely serve to exemplify the proposed irregularity; these data were obtained from *tottering* mice [11], which sometimes also exhibit similar paroxysmal dyskinesia attacks. The red asterisks above the example of irregular PC activity depict the occurrence of complex spikes. SC indicates the spinal cord, receiving input from Cx.

associated PKD should be aimed at bridging the gap in our current understanding at the *in vitro* and *in vivo* level, with specific emphasis on uncovering the circuit mechanisms that may explain the duration of the paroxysmal episode. First, combined interventional and electrophysiological experiments *in vivo* may unravel where the effects of distinct triggers like epileptogenic activity and hyperthermia converge with enhanced granule cell activity and lead to prolonged periods of putative irregular cerebellar firing. Next, simultaneous electrophysiological recordings of Purkinje cells and cerebellar nuclei neurons in awake behaving animals during the induction of dyskinesia attacks *in vivo* may reveal whether erratic interactions between the cerebellar cortex and nuclei

indeed occur during episodes of PKD and whether the excitatory feedback is critical for its maintenance (Figure 1). By generating the current *PRRT2*-deficient animal models exhibiting dyskinesia phenotypes and elucidating the primary molecular and cell physiological mechanisms, Tan and colleagues have provided an excellent framework to further expand upon with systems-pathophysiological means.

Lieke Kros¹, Chris I De Zeeuw^{1,2}

¹Department of Neuroscience, Erasmus MC Rotterdam, the Netherlands; ²Netherlands Institute for Neuroscience, Royal Dutch Academy for Arts and Sciences, Amsterdam, the Netherlands
Correspondence: Chris I De Zeeuw
E-mail: c.dezeeuw@erasmusmc.nl

References

- Chen WJ, Lin Y, Xiong ZQ, *et al.* *Nat Genet* 2011; **43**:1252-1255.
- Tan GH, Liu YY, Wang L, *et al.* *Cell Res* 2017; **28**:90-110.
- Valente P, Castroflorio E, Rossi P, *et al.* *Cell Rep* 2016; **15**:117-131.
- Stelzl U, Worm U, Lalowski M, *et al.* *Cell* 2005; **122**:957-968.
- Ebrahimi-Fakhari D, Saffari A, Westenberg A, *et al.* *Brain* 2015; **138**:3476-3495.
- Chen CH, Fremont R, Arteaga-Bracho EE, *et al.* *Nat Neurosci* 2014; **17**:1767-1775.
- Fremont R, Calderon DP, Maleki S, *et al.* *J Neurosci* 2014; **34**:11723-11732.
- Isaksen TJ, Kros L, Vedovato N, *et al.* *PLoS Genet* 2017; **13**:e1006763.
- Hoebek FE, Stahl JS, Van Alphen AM, *et al.* *Neuron* 2005; **45**:953-965.
- Gao Z, Proietti-Onori M, Lin Z, *et al.* *Neuron* 2016; **89**:645-657.
- Kros L, Eelkman Rooda OH, Spanke JK, *et al.* *Ann Neurol* 2015; **77**:1027-1049.